Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Inclusion Criteria: * Diagnosis of cohort: FVII deficiency, Glanzmann Thrombasthenia, or hemophilia A with inhibitors * Male or female, age 12 or older * History of frequent bleeding episodes * Affirmation of informed consent with signature confirmation and assent for children between ages 12 to 17 before any study related activities * Agreement to use highly effective birth control throughout the study if the subject has childbearing potential Exclusion Criteria: * Genotype of FVIID subjects with identified mutations by central lab at screening * Previous participation in a clinical trial evaluating a modified rFVIIa agent * Received an investigational drug within 30 days or 5 half-lives or absence of clinical effect, whichever is longer * Known hypersensitivity to trial or related product * Known positive antibody to FVII or FVIIa detected by central lab at screening * Be immunosuppressed * Significant contraindication to participate